|Ms. Daphne Zohar||Founder, CEO & Exec. Director||1.24M||N/A||1971|
|Dr. Bennett M. Shapiro M.D.||Co-Founder & Board Advisor||95k||N/A||1940|
|Dr. Robert S. Langer Jr., Ph.D., Sc.D., SCD||Co-Founder & Non-Exec. Director||245k||N/A||1949|
|Dr. Bharatt M. Chowrira||Pres, Chief of Bus. & Strategy, Sec. and Exec. Director||N/A||N/A||1965|
|Dr. David R. Elmaleh Ph.D.||Co-Founder & Sr. Advisor||N/A||N/A||1948|
|Dr. George Farmer Ph.D.||Chief Financial Officer||N/A||N/A||N/A|
|Dr. Joseph B. Bolen||Chief Scientific Officer||N/A||N/A||1954|
|Ms. Allison Mead Talbot||Head of Communications & Investor Relations||N/A||N/A||N/A|
|Mr. Spencer Ball||Sr. VP of HR||N/A||N/A||N/A|
|Dr. Eric Elenko||Chief Innovation Officer||N/A||N/A||1973|
PureTech Health plc, a clinical stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and dementia-related psychosis; a hydrogel platform technology to treat obesity and other chronic metabolic diseases; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; a immunomodulation platform to treat chronic and acute inflammatory disorders; therapies for immune-mediated diseases based on a rationally-defined consortia of human microbiome-derived bacteria; and a digital treatments to treat cognitive dysfunction associated with neurology and psychiatry conditions. It also provides hematopoietic stem cell based therapies to treat hematological malignancies; a voice-based technology platform to measure health when a person speaks; and a technology platform for the oral delivery of biologics, vaccines, and other drugs. In addition, the company is developing LYT-100, an oral small molecule drug candidate to treat lymphedema, and other lymphatic flow disorders; LYT-200, a IgG4 monoclonal antibody to target galectin-9; LYT-210, a IgG1 monoclonal antibody; Glyph, a synthetic lymphatic targeting chemistry platform; milk exosome-based technology to enable the oral administration of macromolecule therapeutic payloads; and meningeal lymphatics platform to treat Alzheimer's and Parkinson's diseases. PureTech Health plc has collaboration and license agreements with Boehringer Ingelheim International GMBH; Roche Holding AG; Eli Lilly and Company; Imbrium Therapeutics L.P.; and Shionogi & Co., Ltd. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
PureTech Health plc’s ISS Governance QualityScore as of September 26, 2021 is 9. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 1; Compensation: 10.